Serotonin Uptake Inhibitors

• 

  Subject Areas on Research

  • "Power" of selective serotonin reuptake inhibitors in irritable bowel syndrome. 
  • 24- and 36-week outcomes for the Child/Adolescent Anxiety Multimodal Study (CAMS). 
  • A double-blind combination study of clonazepam with sertraline in obsessive-compulsive disorder. 
  • A double-blind comparison of sertraline and fluoxetine in depressed elderly outpatients. 
  • A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A Study). 
  • A multi-site randomized clinical trial to reduce suicidal ideation in suicidal adult outpatients with Major Depressive Disorder: Development of a methodology to enhance safety. 
  • A multicenter, double-blind comparison of the effects of nefazodone and fluoxetine on sleep architecture and quality of sleep in depressed outpatients. 
  • A new model of the blood--brain barrier: co-culture of neuronal, endothelial and glial cells under dynamic conditions. 
  • A pilot randomized controlled trial with paroxetine for subthreshold PTSD in Operation Enduring Freedom/Operation Iraqi Freedom era veterans. 
  • A placebo-controlled trial of bupropion SR in the treatment of chronic posttraumatic stress disorder. 
  • A placebo-controlled, randomized clinical trial comparing sertraline and imipramine for the treatment of dysthymia. 
  • A pooled analysis of gender and trauma-type effects on responsiveness to treatment of PTSD with venlafaxine extended release or placebo. 
  • A possible role of recurrent major depression in risk of fracture. 
  • A psychometric evaluation of the CDRS and MADRS in assessing depressive symptoms in children. 
  • A randomized controlled trial of paroxetine for noncardiac chest pain. 
  • A randomized, controlled, trial of controlled release paroxetine in fibromyalgia. 
  • A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. 
  • A randomized, placebo-controlled study of the efficacy and safety of sertraline in the treatment of the behavioral manifestations of Alzheimer's disease in outpatients treated with donepezil. 
  • A systematic review of newer pharmacotherapies for depression in adults: evidence report summary. 
  • Acceptability of second-step treatments to depressed outpatients: a STAR*D report. 
  • Acute 5-HT reuptake blockade potentiates human amygdala reactivity. 
  • Acute time to response in the Treatment for Adolescents with Depression Study (TADS). 
  • Adjunctive 5-Hydroxytryptophan Slow-Release for Treatment-Resistant Depression: Clinical and Preclinical Rationale. 
  • Adjuvant trazodone in the treatment of alcoholism: an open study. 
  • Adolescent male rats are less sensitive than adults to the anxiogenic and serotonin-releasing effects of fenfluramine. 
  • Advances in Pharmacotherapy of Late-Life Depression. 
  • Adverse Effects of Pharmacologic Treatments of Major Depression in Older Adults. 
  • Alterations in acylcarnitines, amines, and lipids inform about the mechanism of action of citalopram/escitalopram in major depression. 
  • Alterations in serotonin transporter expression in brain regions of rats exposed neonatally to chlorpyrifos. 
  • Amitifadine, a triple reuptake inhibitor, reduces self-administration of the opiate remifentanil in rats. 
  • An 8-week multicenter, parallel-group, double-blind, placebo-controlled study of sertraline in elderly outpatients with major depression. 
  • An exploratory analysis of the impact of family functioning on treatment for depression in adolescents. 
  • An open pilot study of the combination of escitalopram and bupropion-SR for outpatients with major depressive disorder. 
  • Analysis of electrocardiographic data following use of paroxetine in pediatric depression and obsessive-compulsive disorder. 
  • Antidepressant medications and their association with invasive breast cancer and carcinoma in situ of the breast. 
  • Antidepressant pharmacotherapy in the treatment of depression in the very old: a randomized, placebo-controlled trial. 
  • Antidepressant treatment and worsening white matter on serial cranial magnetic resonance imaging in the elderly: the Cardiovascular Health Study. 
  • Antidepressant use, depression, and survival in patients with heart failure. 
  • Antidepressants in pregnancy: a review of commonly prescribed medications. 
  • Anxiety Disorders in Caucasian and African American Children: A Comparison of Clinical Characteristics, Treatment Process Variables, and Treatment Outcomes. 
  • Are SSRIs better than TCAs? Comparison of SSRIs and TCAs: a meta-analysis. 
  • Assessment and treatment of depression in patients with cardiovascular disease: National Heart, Lung, and Blood Institute Working Group Report. 
  • Assessment of safety and long-term outcomes of initial treatment with placebo in TADS. 
  • Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression. 
  • Association between selective serotonin-reuptake inhibitor therapy and heart valve regurgitation. 
  • Association between treatment-emergent suicidal ideation with citalopram and polymorphisms near cyclic adenosine monophosphate response element binding protein in the STAR*D study. 
  • Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohort. 
  • Association of obesity and inflammatory marker levels on treatment outcome: results from a double-blind, randomized study of adjunctive L-methylfolate calcium in patients with MDD who are inadequate responders to SSRIs. 
  • Atypical neuroleptic malignant syndrome caused by clozapine and venlafaxine: early brief treatment with dantrolene. 
  • Augmentation of sertraline with prolonged exposure in the treatment of posttraumatic stress disorder. 
  • Autoreceptor control of serotonin dynamics. 
  • Baseline depression severity as a predictor of single and combination antidepressant treatment outcome: results from the CO-MED trial. 
  • Benefits of child-focused anxiety treatments for parents and family functioning. 
  • Best clinical practice: guidelines for managing major depression in primary medical care. 
  • Biological therapies for posttraumatic stress disorder: an overview. 
  • Blinding and bias in a hypnotic clinical trial. 
  • Botulinum toxin treatment of social anxiety disorder with hyperhidrosis: a placebo-controlled double-blind trial. 
  • Bupropion in the treatment of outpatients with asthma and major depressive disorder. 
  • Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. 
  • Bursts and the efficacy of selective serotonin reuptake inhibitors. 
  • Can phase III trial results of antidepressant medications be generalized to clinical practice? A STAR*D report. 
  • Cardiology Patient Page. Depression after heart attack: why should I be concerned about depression after a heart attack? 
  • Child/Adolescent anxiety multimodal study: evaluating safety. 
  • Childhood abuse and treatment response in patients with irritable bowel syndrome: a post-hoc analysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled release. 
  • Citalopram and quality of life in lung transplant recipients. 
  • Clinical and demographic features of atypical depression in outpatients with major depressive disorder: preliminary findings from STAR*D. 
  • Clinical and sociodemographic characteristics associated with suicidal ideation in depressed outpatients. 
  • Clinical correlates of the worsening or emergence of suicidal ideation during SSRI treatment of depression: an examination of citalopram in the STAR*D study. 
  • Clinical experience using appetite suppressants and SSRIs. 
  • Clinical experience with substance P receptor (NK1) antagonists in depression. 
  • Clinical features of depressed outpatients with and without co-occurring general medical conditions in STAR*D. 
  • Clinical features of patients with treatment-emergent suicidal behavior following initiation of paroxetine therapy. 
  • Clinical trial evidence for treatment of depression in heart failure. 
  • Clinical use of nefazodone in major depression: a 6-year perspective. 
  • Cognitive behavior therapy augmentation of pharmacotherapy in pediatric obsessive-compulsive disorder: the Pediatric OCD Treatment Study II (POTS II) randomized controlled trial. 
  • Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety. 
  • Cognitive measures of adolescent depression: unique or unitary constructs? 
  • Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D report. 
  • Combination pharmacotherapy: a mixture of small doses of naltrexone, fluoxetine, and a thyrotropin-releasing hormone analogue reduces alcohol intake in three strains of alcohol-preferring rats. 
  • Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. 
  • Common genetic variation in the indoleamine-2,3-dioxygenase genes and antidepressant treatment outcome in major depressive disorder. 
  • Comparative effects of nefazodone and fluoxetine on sleep in outpatients with major depressive disorder. 
  • Comparative efficacy of cognitive behavioral therapy, fluoxetine, and their combination in depressed adolescents: initial lessons from the treatment for adolescents with depression study. 
  • Concise Associated Symptoms Tracking scale: a brief self-report and clinician rating of symptoms associated with suicidality. 
  • Concise Health Risk Tracking scale: a brief self-report and clinician rating of suicidal risk. 
  • Consensus statement on depression, anxiety, and cardiovascular disease. 
  • Consensus statement on panic disorder from the International Consensus Group on Depression and Anxiety. 
  • Consensus statement on posttraumatic stress disorder from the International Consensus Group on Depression and Anxiety. 
  • Continued cognitive-behavior therapy versus sertraline for children and adolescents with obsessive-compulsive disorder that were non-responders to cognitive-behavior therapy: a randomized controlled trial. 
  • Cost-effectiveness of treatments for adolescent depression: results from TADS. 
  • Davidson Trauma Scale (DTS): normative scores in the general population and effect sizes in placebo-controlled SSRI trials. 
  • Defining treatment response and remission in child anxiety: signal detection analysis using the pediatric anxiety rating scale. 
  • Depression and Long-Term Prescription Opioid Use and Opioid Use Disorder: Implications for Pain Management in Cancer. 
  • Depression and heart failure: the lonely comorbidity. 
  • Depression and insomnia in women. 
  • Depression and ischemic heart disease: what have we learned from clinical trials? 
  • Depression and late mortality after myocardial infarction in the Enhancing Recovery in Coronary Heart Disease (ENRICHD) study. 
  • Depression as a risk factor for coronary artery disease: evidence, mechanisms, and treatment. 
  • Depression in Maltreated Children and Adolescents. 
  • Depression, coronary events, platelet inhibition, and serotonin reuptake inhibitors. 
  • Desvenlafaxine, a serotonin-norepinephrine uptake inhibitor for major depressive disorder, neuropathic pain and the vasomotor symptoms associated with menopause. 
  • Developing the evidence for evidence-based practice. 
  • Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. 
  • Differential neural responses to food images in women with bulimia versus anorexia nervosa. 
  • Difficult behaviors in long-term care patients with dementia. 
  • Distinct trajectories of long-term symptom severity in pediatric obsessive-compulsive disorder during and after stepped-care treatment. 
  • Do menopausal status and use of hormone therapy affect antidepressant treatment response? Findings from the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study. 
  • Does comorbid substance use disorder impair recovery from major depression with SSRI treatment? An analysis of the STAR*D level one treatment outcomes. 
  • Does the duration of index episode affect the treatment outcome of major depressive disorder? A STAR*D report. 
  • Drugs of the psychopharmacological revolution in clinical psychiatry. 
  • Dystonia as a side effect of nonneuroleptics. 
  • ERICH3: vesicular association and antidepressant treatment response. 
  • Early adverse events and attrition in selective serotonin reuptake inhibitor treatment: a suicide assessment methodology study report. 
  • Early pharmacological treatment of autism: a rationale for developmental treatment. 
  • Easing the burden of social anxiety disorder. 
  • Effect of Exercise, Escitalopram, or Placebo on Anxiety in Patients With Coronary Heart Disease: The Understanding the Benefits of Exercise and Escitalopram in Anxious Patients With Coronary Heart Disease (UNWIND) Randomized Clinical Trial. 
  • Effect of Sertraline on Depressive Symptoms in Patients With Chronic Kidney Disease Without Dialysis Dependence: The CAST Randomized Clinical Trial. 
  • Effect of age at onset on the course of major depressive disorder. 
  • Effect of antidepressants and psychological therapies, including hypnotherapy, in irritable bowel syndrome: systematic review and meta-analysis. 
  • Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. 
  • Effect of escitalopram on mental stress-induced myocardial ischemia: results of the REMIT trial. 
  • Effect of selective serotonin reuptake inhibitors on platelets in patients with coronary artery disease. 
  • Effect of selective serotonin reuptake inhibitors on the risk of fracture. 
  • Effects of Exercise and Sertraline on Measures of Coronary Heart Disease Risk in Patients With Major Depression: Results From the SMILE-II Randomized Clinical Trial. 
  • Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction. 
  • Effects of coping skills training and sertraline in patients with non-cardiac chest pain: a randomized controlled study. 
  • Effects of fluoxetine at antidepressant doses on short-term outcome of detoxified alcoholics. 
  • Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) Randomized Trial. 
  • Efficacy and safety of extended-release venlafaxine in the treatment of generalized anxiety disorder in children and adolescents: two placebo-controlled trials. 
  • Efficacy and tolerability of antidepressants in pediatric anxiety disorders: a systematic review and meta-analysis. 
  • Efficacy and tolerability of duloxetine in elderly patients with generalized anxiety disorder: a pooled analysis of four randomized, double-blind, placebo-controlled studies. 
  • Efficacy of newer medications for treating depression in primary care patients. 
  • Escitalopram in clinical practice: results of an open-label trial in a naturalistic setting. 
  • Escitalopram in specific phobia: results of a placebo-controlled pilot trial. 
  • Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study. 
  • Escitalopram treatment of trichotillomania. 
  • Establishing the neurobiologic basis of treatment in children and adolescents with generalized anxiety disorder. 
  • Eszopiclone coadministered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. 
  • Evaluation of eszopiclone discontinuation after cotherapy with fluoxetine for insomnia with coexisting depression. 
  • Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. 
  • Evidence-based clinical practice guidelines for managing depression in persons living with HIV. 
  • Examining Parental Medication Adherence as a Predictor of Child Medication Adherence in Pediatric Anxiety Disorders. 
  • Extreme thinking in clinically depressed adolescents: Results from the Treatment for Adolescents with Depression Study (TADS). 
  • Factor structure and psychometric properties of the Children's Negative Cognitive Error Questionnaire with a clinically depressed adolescent sample. 
  • Factors associated with health-related quality of life among outpatients with major depressive disorder: a STAR*D report. 
  • Fluorine magnetic resonance spectroscopy measurement of brain fluvoxamine and fluoxetine in pediatric patients treated for pervasive developmental disorders. 
  • Fluoxetine Maintains a State of Heightened Responsiveness to Motor Training Early After Stroke in a Mouse Model. 
  • Fluoxetine versus placebo in preventing relapse of major depression in children and adolescents. 
  • Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. 
  • Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia. 
  • Fluvoxamine and enuresis. 
  • Fluvoxamine for the treatment of anxiety disorders in children and adolescents. The Research Unit on Pediatric Psychopharmacology Anxiety Study Group. 
  • Fluvoxamine in civilians with posttraumatic stress disorder. 
  • Fluvoxamine treatment in veterans with combat-related post-traumatic stress disorder. 
  • Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled study. 
  • Fluvoxamine versus clomipramine for obsessive-compulsive disorder: a double-blind comparison. 
  • Folate metabolism genes, dietary folate and response to antidepressant medications in late-life depression. 
  • Functional connectivity predictors of acute depression treatment outcome. 
  • Functioning and quality of life in the Treatment for Adolescents with Depression Study (TADS). 
  • Generalized anxiety disorder: acute and chronic treatment. 
  • Generalized social anxiety disorder and avoidant personality disorder: structural analysis and treatment outcome. 
  • Genetic markers of suicidal ideation emerging during citalopram treatment of major depression. 
  • Genome-wide association study of suicidal ideation emerging during citalopram treatment of depressed outpatients. 
  • Glycine and a glycine dehydrogenase (GLDC) SNP as citalopram/escitalopram response biomarkers in depression: pharmacometabolomics-informed pharmacogenomics. 
  • Goldenhar syndrome associated with prenatal maternal Fluoxetine ingestion: Cause or coincidence? 
  • Herbal supplements: Widely used, poorly understood. 
  • High-dose escitalopram in the treatment of binge-eating disorder with obesity: a placebo-controlled monotherapy trial. 
  • High-dose sertraline strategy for nonresponders to acute treatment for obsessive-compulsive disorder: a multicenter double-blind trial. 
  • Hydroxychloroquine-induced hyperpigmentation: the staining pattern. 
  • Hyperhidrosis in social anxiety disorder. 
  • Hyperreactive platelet phenotypes: relationship to altered serotonin transporter number, transport kinetics and intrinsic response to adrenergic co-stimulation. 
  • Hypothesis: antiplatelet effects of selective serotonin reuptake inhibitors cause clinical benefits on cardiovascular disease and increase risks of bleeding. 
  • Identifying risk for attrition during treatment for depression. 
  • Identifying serotonergic mechanisms underlying the corticolimbic response to threat in humans. 
  • Impact of depressive symptoms on the treatment of generalized social anxiety disorder. 
  • Impact of sleep complaints and depression outcomes among participants in the standard medical intervention and long-term exercise study of exercise and pharmacotherapy for depression. 
  • Impact of treatment improvement on long-term anxiety: Results from CAMS and CAMELS. 
  • Improvement of anger at one week predicts the effects of sertraline and placebo in PTSD. 
  • Improving the prediction of treatment response in depression: integration of clinical, cognitive, psychophysiological, neuroimaging, and genetic measures. 
  • Income and attrition in the treatment of depression: a STAR*D report. 
  • Increase in work productivity of depressed individuals with improvement in depressive symptom severity. 
  • Increased ventromedial prefrontal cortex activity and connectivity predict poor sertraline treatment outcome in late-life depression. 
  • Indicators of pretreatment suicidal ideation in adults with major depressive disorder. 
  • Inflammation Markers and Major Depressive Disorder in Patients With Chronic Heart Failure: Results From the Sertraline Against Depression and Heart Disease in Chronic Heart Failure Study. 
  • Inflammation-Induced Histamine Impairs the Capacity of Escitalopram to Increase Hippocampal Extracellular Serotonin. 
  • Insight and treatment outcome in obsessive-compulsive disorder. 
  • International Study to Predict Optimized Treatment for Depression (iSPOT-D), a randomized clinical trial: rationale and protocol. 
  • Kava in generalized anxiety disorder: three placebo-controlled trials. 
  • L-methylfolate as adjunctive therapy for SSRI-resistant major depression: results of two randomized, double-blind, parallel-sequential trials. 
  • Long-lasting delayed hyperalgesia after subchronic swim stress. 
  • Long-term treatment and prevention of posttraumatic stress disorder. 
  • Longer term benefits of exercise and escitalopram in the treatment of anxiety in patients with coronary heart disease: Six month follow-up of the UNWIND randomized clinical trial. 
  • Maintenance phase efficacy of sertraline for chronic depression: a randomized controlled trial. 
  • Management of Menopausal Symptoms for Women Who Are at High Risk of Thrombosis. 
  • Marked differences in antidepressant use by race in an elderly community sample: 1986-1996. 
  • Mediators of change in the Child/Adolescent Anxiety Multimodal Treatment Study. 
  • Mediators of youth anxiety outcomes 3 to 12 years after treatment. 
  • Medication augmentation after the failure of SSRIs for depression. 
  • Medication optimization during clozapine treatment. 
  • Mental stress-induced left ventricular dysfunction and adverse outcome in ischemic heart disease patients. 
  • Merging pharmacometabolomics with pharmacogenomics using '1000 Genomes' single-nucleotide polymorphism imputation: selective serotonin reuptake inhibitor response pharmacogenomics. 
  • Metabolomic signature of exposure and response to citalopram/escitalopram in depressed outpatients. 
  • Milnacipran: beyond a role of antidepressant. 
  • Models of dopaminergic and serotonergic signaling. 
  • Multi-informant Expectancies and Treatment Outcomes for Anxiety in Youth. 
  • Multicenter, double-blind comparison of sertraline and placebo in the treatment of posttraumatic stress disorder. 
  • Multidimensional effects of sertraline in social anxiety disorder. 
  • Naturalistic study of the early psychiatric use of citalopram in the United States. 
  • Neural control of the urethra and development of pharmacotherapy for stress urinary incontinence. 
  • New drugs for old folks: the evidence-based argument for newer antidepressants. 
  • Off-label applications for SSRIs. 
  • Off-label uses for selective serotonin reuptake inhibitors. 
  • Olanzapine and fluoxetine administration and coadministration increase rat hippocampal pregnenolone, allopregnanolone and peripheral deoxycorticosterone: implications for therapeutic actions. 
  • Olanzapine increases allopregnanolone in the rat cerebral cortex. 
  • Onset of activity and time to response on individual CAPS-SX17 items in patients treated for post-traumatic stress disorder with venlafaxine ER: a pooled analysis. 
  • Open-label phase 1b pilot study to assess the antiviral efficacy of simvastatin combined with sertraline in chronic hepatitis C patients. 
  • Outcome at 6 months for 50 adolescents with major depression treated in a health maintenance organization. 
  • Pain in depression: STAR*D study findings. 
  • Panic disorder and social phobia: current treatments and new strategies. 
  • Parental anxiety as a predictor of medication and CBT response for anxious youth. 
  • Paroxetine CR augmentation for posttraumatic stress disorder refractory to prolonged exposure therapy. 
  • Paroxetine in the treatment of generalised anxiety disorder. 
  • Paroxetine in the treatment of post-traumatic stress disorder: pooled analysis of placebo-controlled studies. 
  • Paroxetine: safety and tolerability issues. 
  • Partial remission. A common outcome in older adults treated for major depression. 
  • Patient beliefs predict response to paroxetine among primary care patients with dysthymia and minor depression. 
  • Pediatric pain syndromes and management of pain in children and adolescents with rheumatic disease. 
  • Perioperative Selective Serotonin Reuptake Inhibitor Use Is Associated With an Increased Risk of Transfusion in Total Hip and Knee Arthroplasty. 
  • Pharmacoeconomic analysis of sertraline treatment of depression in patients with unstable angina or a recent myocardial infarction. 
  • Pharmacogenetic analysis of genes implicated in rodent models of antidepressant response: association of TREK1 and treatment resistance in the STAR(*)D study. 
  • Pharmacogenetics studies in STAR*D: strengths, limitations, and results. 
  • Pharmacogenomics-Driven Prediction of Antidepressant Treatment Outcomes: A Machine-Learning Approach With Multi-trial Replication. 
  • Pharmacokinetic-Pharmacodynamic interaction associated with venlafaxine-XR remission in patients with major depressive disorder with history of citalopram / escitalopram treatment failure. 
  • Pharmacologic treatment of acute and chronic stress following trauma: 2006. 
  • Pharmacometabolomic mapping of early biochemical changes induced by sertraline and placebo. 
  • Pharmacometabolomics of response to sertraline and to placebo in major depressive disorder - possible role for methoxyindole pathway. 
  • Pharmacometabolomics: implications for clinical pharmacology and systems pharmacology. 
  • Pharmacotherapy of posttraumatic stress disorder: treatment options, long-term follow-up, and predictors of outcome. 
  • Pharmacotherapy of social anxiety disorder. 
  • Pharmacotherapy of social phobia. 
  • Placebo Response in Pediatric Anxiety Disorders: Results from the Child/Adolescent Anxiety Multimodal Study. 
  • Placebo-controlled trial of risperidone augmentation for selective serotonin reuptake inhibitor-resistant civilian posttraumatic stress disorder. 
  • Platelet aggregation and mental stress induced myocardial ischemia: Results from the Responses of Myocardial Ischemia to Escitalopram Treatment (REMIT) study. 
  • Platelet inhibition by sertraline and N-desmethylsertraline: a possible missing link between depression, coronary events, and mortality benefits of selective serotonin reuptake inhibitors. 
  • Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. 
  • Post-traumatic stress disorder: an evaluation of existing pharmacotherapies and new strategies. 
  • Prediction of short-term antidepressant response using probabilistic graphical models with replication across multiple drugs and treatment settings. 
  • Predictors and moderators of acute outcome in the Treatment for Adolescents with Depression Study (TADS). 
  • Predictors and moderators of treatment outcome in the Pediatric Obsessive Compulsive Treatment Study (POTS I). 
  • Predictors and moderators of treatment response in childhood anxiety disorders: results from the CAMS trial. 
  • Predictors associated with improved cognitive-behavioral therapy outcome in pediatric obsessive-compulsive disorder. 
  • Predictors of antidepressant use among older adults: have they changed over time? 
  • Predictors of attrition during initial (citalopram) treatment for depression: a STAR*D report. 
  • Predictors of nonresponse to treatment in primary care patients with dysthymia. 
  • Pretreatment metabotype as a predictor of response to sertraline or placebo in depressed outpatients: a proof of concept. 
  • Pretreatment metabotype as a predictor of response to sertraline or placebo in depressed outpatients: a proof of concept. 
  • Prevalence of depression and its treatment in an elderly population: the Cache County study. 
  • Priapism associated with venlafaxine use. 
  • Primary versus specialty care outcomes for depressed outpatients managed with measurement-based care: results from STAR*D. 
  • Prognosis of patients taking selective serotonin reuptake inhibitors before coronary artery bypass grafting. 
  • Programming of brainstem serotonin transporter development by prenatal glucocorticoids. 
  • Proton pump inhibitors may enhance the risk of citalopram- and escitalopram-associated sudden cardiac death among patients receiving hemodialysis. 
  • Psychiatric sequelae of traumatic brain injury: a case report. 
  • Psychopharmacologic treatment of children and adolescents with anxiety disorders. 
  • Psychosocial treatment within sex by ethnicity subgroups in the Enhancing Recovery in Coronary Heart Disease clinical trial. 
  • QT interval prolongation and torsades de pointes in a patient undergoing treatment with vorinostat: a case report and review of the literature. 
  • Quality of life in geriatric depression: a comparison of remitters, partial responders, and nonresponders. 
  • Randomized comparison of selective serotonin reuptake inhibitor (escitalopram) monotherapy and antidepressant combination pharmacotherapy for major depressive disorder with melancholic features: a CO-MED report. 
  • Randomized trial of sertraline in patients with unexplained chest pain of noncardiac origin. 
  • Randomized, placebo-controlled trial of fluoxetine for acute treatment of minor depressive disorder. 
  • Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. 
  • Recursive subsetting to identify patients in the STAR*D: a method to enhance the accuracy of early prediction of treatment outcome and to inform personalized care. 
  • Reducing Suicidal Ideation Through Insomnia Treatment (REST-IT): A Randomized Clinical Trial. 
  • Relapse of depression after electroconvulsive therapy. 
  • Relapse of depressive symptoms after discontinuing sertraline. 
  • Relationship between release of platelet/endothelial biomarkers and plasma levels of sertraline and N-desmethylsertraline in acute coronary syndrome patients receiving SSRI treatment for depression. 
  • Remission after acute treatment in children and adolescents with anxiety disorders: findings from the CAMS. 
  • Remission and recovery in the Treatment for Adolescents with Depression Study (TADS): acute and long-term outcomes. 
  • Remission and residual symptoms after short-term treatment in the Treatment of Adolescents with Depression Study (TADS). 
  • Research knowledge among the participants in the Treatment for Adolescents With Depression Study (TADS). 
  • Resolution of fear of flying with fluoxetine treatment. 
  • Response in relation to baseline anxiety levels in major depressive disorder treated with bupropion sustained release or sertraline. 
  • Response to a selective serotonin reuptake inhibitor (citalopram) in major depressive disorder with melancholic features: a STAR*D report. 
  • Responses of mental stress-induced myocardial ischemia to escitalopram treatment: background, design, and method for the Responses of Mental Stress Induced Myocardial Ischemia to Escitalopram Treatment trial. 
  • Results From the Child/Adolescent Anxiety Multimodal Extended Long-Term Study (CAMELS): Primary Anxiety Outcomes. 
  • Results from the Child/Adolescent Anxiety Multimodal Longitudinal Study (CAMELS): Functional outcomes. 
  • Review of evidence for genetic testing for CYP450 polymorphisms in management of patients with nonpsychotic depression with selective serotonin reuptake inhibitors. 
  • Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivity. 
  • SLC6A4 variation and citalopram response. 
  • SSRI Augmentation by 5-Hydroxytryptophan Slow Release: Mouse Pharmacodynamic Proof of Concept. 
  • SSRI/SNRI Therapy is Associated With a Higher Risk of Gastrointestinal Bleeding in LVAD Patients. 
  • Safety and efficacy of escitalopram in the long-term treatment of generalized anxiety disorder. 
  • Safety of selective serotonin reuptake inhibitor use prior to coronary artery bypass grafting. 
  • Secondary outcomes from the pediatric obsessive compulsive disorder treatment study II. 
  • Selective Serotonin Reuptake Inhibitors and Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation: An Analysis From the ROCKET AF Trial. 
  • Selective Serotonin Reuptake Inhibitors and Intracerebral Hemorrhage Risk and Outcome. 
  • Selective serotonin reuptake inhibitors for fibromyalgia syndrome. 
  • Selective serotonin reuptake inhibitors for fibromyalgia syndrome. 
  • Selective serotonin reuptake inhibitors in post-traumatic stress disorder. 
  • Selective serotonin reuptake inhibitors yield additional antiplatelet protection in patients with congestive heart failure treated with antecedent aspirin. 
  • Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. 
  • Serotonergic modulation of bladder afferent pathways. 
  • Sertraline Pediatric Registry for the Evaluation of Safety: Design and Clinical Characteristics of Pediatric Patients Prescribed Sertraline. 
  • Sertraline and the Cheshire cat in geriatric depression. 
  • Sertraline attenuates hyperphagia in rats following nicotine withdrawal. 
  • Sertraline for treatment of depression in acute coronary syndromes. 
  • Sertraline treatment of major depression in patients with acute MI or unstable angina. 
  • Sertraline-induced potentiation of the CYP3A4-dependent neurotoxicity of carbamazepine: an in vitro study. 
  • Should selective serotonin reuptake inhibitors be prescribed to all patients with ischemic heart disease? 
  • Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial. 
  • Simultaneous Benzodiazepine and SSRI Initiation in Young People With Anxiety Disorders. 
  • Sleep-Related Problems and the Effects of Anxiety Treatment in Children and Adolescents. 
  • Slow-release delivery enhances the pharmacological properties of oral 5-hydroxytryptophan: mouse proof-of-concept. 
  • Social phobia: issues in assessment and management. 
  • Sociodemographic, clinical, and treatment characteristics associated with worsened depression during treatment with citalopram: results of the NIMH STAR(*)D trial. 
  • Somatic complaints in anxious youth. 
  • Star-D: lessons learned and future implications. 
  • Status of minor depression or dysthymia in primary care following a randomized controlled treatment. 
  • Still Struggling: characteristics of youth with OCD who are partial responders to medication treatment. 
  • Study refusal and exclusion from a randomized treatment study of generalized social phobia. 
  • Suicidal events in the Treatment for Adolescents With Depression Study (TADS). 
  • Support for the vascular depression hypothesis in late-life depression: results of a 2-site, prospective, antidepressant treatment trial. 
  • Symptom-specific effects of cognitive-behavioral therapy, sertraline, and their combination in a large randomized controlled trial of pediatric anxiety disorders. 
  • TSPAN5, ERICH3 and selective serotonin reuptake inhibitors in major depressive disorder: pharmacometabolomics-informed pharmacogenomics. 
  • Testing for cytochrome P450 polymorphisms in adults with non-psychotic depression treated with selective serotonin reuptake inhibitors (SSRIs). 
  • Texas Children's Medication Algorithm Project: update from Texas Consensus Conference Panel on Medication Treatment of Childhood Major Depressive Disorder. 
  • The Effects of Youth Anxiety Treatment on School Impairment: Differential Outcomes Across CBT, Sertraline, and their Combination. 
  • The Impact of Treatment Expectations on Exposure Process and Treatment Outcome in Childhood Anxiety Disorders. 
  • The STAR*D Project results: a comprehensive review of findings. 
  • The Treatment for Adolescents With Depression Study (TADS): long-term effectiveness and safety outcomes. 
  • The Treatment for Adolescents With Depression Study (TADS): outcomes over 1 year of naturalistic follow-up. 
  • The Treatment for Adolescents with Depression Study (TADS): methods and message at 12 weeks. 
  • The alpha(2a)-adrenergic receptor plays a protective role in mouse behavioral models of depression and anxiety. 
  • The feasibility of a randomised, placebo-controlled clinical trial of homeopathic treatment of depression in general practice. 
  • The impact of chronic depression on acute and long-term outcomes in a randomized trial comparing selective serotonin reuptake inhibitor monotherapy versus each of 2 different antidepressant medication combinations. 
  • The relationship between adverse events during selective serotonin reuptake inhibitor treatment for major depressive disorder and nonremission in the suicide assessment methodology study. 
  • The selective serotonin reuptake inhibitor citalopram induces the storage of serotonin in catecholaminergic terminals. 
  • The therapeutic relationship in cognitive-behavioral therapy and pharmacotherapy for anxious youth. 
  • The treatment of chronic depression, part 1: study design and rationale for evaluating the comparative efficacy of sertraline and imipramine as acute, crossover, continuation, and maintenance phase therapies. 
  • The treatment of chronic depression, part 2: a double-blind, randomized trial of sertraline and imipramine. 
  • The treatment of chronic depression, part 3: psychosocial functioning before and after treatment with sertraline or imipramine. 
  • Therapy for chemotherapy-induced peripheral neuropathy--in reply. 
  • Therapy for mental stress-induced myocardial ischemia--reply. 
  • Tic-related obsessive-compulsive disorder (OCD): phenomenology and treatment outcome in the Pediatric OCD Treatment Study II. 
  • Tics Moderate Sertraline, but Not Cognitive-Behavior Therapy Response in Pediatric Obsessive-Compulsive Disorder Patients Who Do Not Respond to Cognitive-Behavior Therapy. 
  • Time to relapse after 6 and 12 months' treatment of generalized anxiety disorder with venlafaxine extended release. 
  • Tolerability of fluoxetine in posttraumatic stress disorder. 
  • Trajectories of Functioning Into Emerging Adulthood Following Treatment for Adolescent Depression. 
  • Trauma, resilience and saliostasis: effects of treatment in post-traumatic stress disorder. 
  • Treating Pediatric Anxiety: Initial Use of SSRIs and Other Antianxiety Prescription Medications. 
  • Treatment considerations for patients with neuropathic pain and other medical comorbidities. 
  • Treatment for Adolescents With Depression Study (TADS): rationale, design, and methods. 
  • Treatment of anxiety in patients with coronary heart disease: Rationale and design of the UNderstanding the benefits of exercise and escitalopram in anxious patients WIth coroNary heart Disease (UNWIND) randomized clinical trial. 
  • Treatment of chronic depression with sertraline or imipramine: preliminary blinded response rates and high rates of undertreatment in the community. 
  • Treatment of mild depression in elderly patients. 
  • Treatment of posttraumatic stress disorder with venlafaxine extended release: a 6-month randomized controlled trial. 
  • Treatment of posttraumatic stress disorder: the impact of paroxetine. 
  • Treatment of social anxiety disorder with citalopram. 
  • Treatment outcome and outcome associations in children with pervasive developmental disorders treated with selective serotonin reuptake inhibitors: a chart review. 
  • Treatment outcomes for older depressed patients with earlier versus late onset of first depressive episode: a Sequenced Treatment Alternatives to Relieve Depression (STAR*D) report. 
  • Treatment response in depressed adolescents with and without co-morbid attention-deficit/hyperactivity disorder in the Treatment for Adolescents with Depression Study. 
  • Trial of trazodone for posttraumatic stress disorder using a multiple baseline group design. 
  • Use of bupropion in combination with serotonin reuptake inhibitors. 
  • Use of selective serotonin reuptake inhibitors and risk of stroke: a systematic review and meta-analysis. 
  • Vintage treatments for PTSD: a reconsideration of tricyclic drugs. 
  • Voltammetric Approach for Characterizing the Biophysical and Chemical Functionality of Human Induced Pluripotent Stem Cell-Derived Serotonin Neurons. 
  • What are the clinical implications of new onset or worsening anxiety during the first two weeks of SSRI treatment for depression? 
  • What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression. 
  • What to Expect When Switching to a Second Antidepressant Medication Following an Ineffective Initial SSRI: A Report From the Randomized Clinical STAR*D Study. 
  • When Discontinuing SSRI Antidepressants Is a Challenge: Management Tips. 
  • Zolpidem for persistent insomnia in SSRI-treated depressed patients. 
  • Zonisamide prevents olanzapine-associated hyperphagia, weight gain, and elevated blood glucose in rats. 
  • [A new quality of the therapy of anxiety and depression--escitalopram]. 
• 

  Keywords of People

  • Bradford, Daniel William, Professor of Psychiatry and Behavioral Sciences, Psychiatry, Child & Family Mental Health & Community Psychiatry
  • O'Connor, Christopher Michael, Richard Sean Stack, M.D. Distinguished Professor, Medicine, Clinical Pharmacology